Abstract 365P
Background
The incidence of pancreatic cancer in young patients has increased over the last decade. This retrospective comparative study aims to identify clinico-pathological characteristics of young patients with pancreatic cancer and to analyse prognostic factors influencing their survival.
Methods
Patients diagnosed with pancreatic cancer at our medical oncology department between 2001 and 2023 were included and divided into two groups: the group of young patients who were under the age of 45 (A group) and the group of older patients over this age limit (B group).
Results
A total of 238 patients were studied. 28 patients (11.7%) were younger than 45 years. Preserved general status (PS 0-1) was more common in B group than A (61.5% vs 53.5%). Synchronous metastases were less frequent in young patients (42.9% vs 45%, p=0.3). Young patients had less often curative surgery (respectively 17.9% vs 33.5% p= 0.3). Relapse after curative surgery were more common in A group (69.3% vs 67.9%; p=0.5). 82.1% of the patients received chemotherapy: gemcitabin -cisplatin was the preferred neoadjuvantregimen in both groups (A group:81.8%), (B) (45.5%). Partial radiological responses were seen in 11.3% in group A and 15.4% in group B. less proportion of young received first and second lines palliative chemotherapy (respectively:39.3 % vs 50.2% and 14.3% vs13.2 %). The most commonly used protocol in first line was LV5 FU2 Cisplatin in group A (36.4%) and gemcitabine in group B (54.1 %). Higher proportion of radiologic progression was noted in older patients after first-line palliative chemotherapy (90.9% vs 100%), All young patients progressed after second line (100% vs 71.6%). PFS was 5 months for group A patients and 6 months in older patients (p =0.5).
Conclusions
Although our results didn’t meet statistical significance, they suggest that young patient with pancreatic cancer seem to have more aggressive tumors, less curative sugery and more relapses after surgery. More aggressive treatments should be recommended for this group of patients.
Legal entity responsible for the study
Medical Oncology Department, University of Sousse.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.